Results 151 to 160 of about 6,619 (182)

Short-Term Effects of Pecavaptan on Weight and Congestion in Acute Heart Failure: The AVANTI Post-Hoc Analysis. [PDF]

open access: yesJACC Adv
Ceelen DCH   +13 more
europepmc   +1 more source

Personalized Sequential Nephron Blockade for Diuretic Resistance in Acute Decompensated Heart Failure: A Narrative Review for the Cardiorenal Clinician. [PDF]

open access: yesJ Pers Med
Gembillo G   +14 more
europepmc   +1 more source

Tolvaptan vs Fluid Restriction in Moderate-Profound Hyponatremia: An Open-Label Randomized Clinical Trial.

open access: yesJ Clin Endocrinol Metab
Warren AM   +5 more
europepmc   +1 more source

Tolvaptan

Nature Reviews Drug Discovery, 2009
In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V(2) receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia.
Uma Yasothan   +2 more
exaly   +3 more sources

Home - About - Disclaimer - Privacy